HLB Life Science Past Earnings Performance
Past criteria checks 3/6
HLB Life Science has been growing earnings at an average annual rate of 11.2%, while the Healthcare industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 3.1% per year. HLB Life Science's return on equity is 29.1%, and it has net margins of 138.3%.
Key information
11.2%
Earnings growth rate
15.1%
EPS growth rate
| Healthcare Industry Growth | 34.2% |
| Revenue growth rate | -3.1% |
| Return on equity | 29.1% |
| Net Margin | 138.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings
May 21
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Revenue & Expenses Breakdown
How HLB Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 90,719 | 125,455 | 16,624 | 5,749 |
| 31 Dec 23 | 97,990 | -5,983 | 16,104 | 5,454 |
| 30 Sep 23 | 101,918 | -74,410 | 13,473 | 4,670 |
| 30 Jun 23 | 120,360 | -46,626 | 13,301 | 4,679 |
| 31 Mar 23 | 114,798 | -30,251 | 11,973 | 4,274 |
| 31 Dec 22 | 99,591 | -54,277 | 10,665 | 4,349 |
| 30 Sep 22 | 87,628 | -56,700 | 10,098 | 4,008 |
| 30 Jun 22 | 61,067 | -20,834 | 8,319 | 3,759 |
| 31 Mar 22 | 58,848 | -44,045 | 8,208 | 4,316 |
| 31 Dec 21 | 53,494 | -49,152 | 7,954 | 3,846 |
| 30 Sep 21 | 57,296 | -28,397 | 7,882 | 3,087 |
| 30 Jun 21 | 62,917 | -63,998 | 7,936 | 2,704 |
| 31 Mar 21 | 70,598 | -45,888 | 7,534 | 1,526 |
| 31 Dec 20 | 91,797 | -55,797 | 7,637 | 1,431 |
| 30 Sep 20 | 102,427 | 3,809 | 9,142 | 1,124 |
| 30 Jun 20 | 112,471 | -20,064 | 9,622 | 1,188 |
| 31 Mar 20 | 118,918 | -26,267 | 9,722 | 1,464 |
| 31 Dec 19 | 114,019 | -7,605 | 9,667 | 1,429 |
| 30 Sep 19 | 111,639 | -43,329 | 9,765 | 1,703 |
| 30 Jun 19 | 107,874 | -31,166 | 9,692 | 1,804 |
| 31 Mar 19 | 105,435 | -23,689 | 10,313 | 1,630 |
| 31 Dec 18 | 102,476 | -18,191 | 10,501 | 1,321 |
| 30 Sep 18 | 105,040 | 9,936 | 8,058 | 940 |
| 30 Jun 18 | 103,643 | 9,613 | 6,857 | 549 |
| 31 Mar 18 | 106,930 | 6,681 | 5,138 | 298 |
| 31 Dec 17 | 106,445 | 7,761 | 3,967 | 243 |
| 30 Sep 17 | 108,191 | 564 | 4,548 | 252 |
| 30 Jun 17 | 84,642 | -906 | 4,702 | 163 |
| 31 Mar 17 | 59,517 | -1,174 | 4,604 | 81 |
| 31 Dec 16 | 42,234 | -1,251 | 3,986 | 81 |
| 30 Sep 16 | 20,970 | -8,003 | 4,474 | 288 |
| 30 Jun 16 | 25,730 | -8,880 | 3,856 | 307 |
| 31 Mar 16 | 29,191 | -15,904 | 4,538 | 346 |
| 31 Dec 15 | 27,323 | -17,041 | 4,818 | 352 |
| 30 Sep 15 | 29,034 | -10,493 | 3,586 | -5 |
| 30 Jun 15 | 34,740 | -7,677 | 3,956 | -24 |
| 31 Mar 15 | 36,580 | 44 | 3,280 | 30 |
| 31 Dec 14 | 36,560 | 1,331 | 3,174 | 24 |
| 30 Sep 14 | 26,921 | -1,595 | 2,914 | 93 |
| 30 Jun 14 | 27,651 | -2,417 | 3,087 | 93 |
| 31 Mar 14 | 22,631 | -3,968 | 2,986 | 0 |
| 31 Dec 13 | 19,956 | -4,446 | 2,891 | 0 |
| 30 Sep 13 | 20,449 | -8,586 | 4,693 | 40 |
Quality Earnings: A067630 has a high level of non-cash earnings.
Growing Profit Margin: A067630 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A067630 has become profitable over the past 5 years, growing earnings by 11.2% per year.
Accelerating Growth: A067630 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A067630 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (6.4%).
Return on Equity
High ROE: A067630's Return on Equity (29.1%) is considered high.